Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FL115 in advanced solid tumors
NCT06130722Phase 1Completed
- Sponsor
- Forlong Biotechnology
- Start
- Dec 2023
- Primary completion
- Feb 2025
- Modality
- Cytokines & Interferons, Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FL-115 in solid tumor, sponsored by Forlong Biotechnology. Primary endpoints: Safety and Tolerability of FL115, Dose-Limiting Toxicity at 28 days and 1 more. Started Dec 2023; status: completed.
02
Drugs
FL-115
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06130722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06130722.